Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BMS-188667 (Bristol-Myers Squibb).

F J Dumont1

  • 1Department of Immunology, Merck Research Laboratories, Rahway, NJ 07065, USA. francis_dumont@merck.com

Idrugs : the Investigational Drugs Journal
|August 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Everolimus. Novartis.

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Treatment of transplant rejection: are the traditional immunosuppressants good enough?

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Alemtuzumab (Millennium/ILEX).

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

FK506, an immunosuppressant targeting calcineurin function.

Current medicinal chemistry·2000
Same author

Hypothemycin inhibits the proliferative response and modulates the production of cytokines during T cell activation.

Immunopharmacology·1999
Same author

C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study.

Bioorganic & medicinal chemistry letters·1999
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Bristol-Myers Squibb is developing CTLA4-Ig, an immunosuppressant immunoglobulin, for immunological disorders. This therapy is currently in Phase II trials for psoriasis and other autoimmune conditions.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Immunological disorders represent a significant unmet medical need.
  • Immunosuppressant therapies are crucial for managing autoimmune diseases and preventing transplant rejection.

Purpose of the Study:

  • To evaluate the therapeutic potential of CTLA4-Ig (abatacept) in various immunological disorders.
  • To assess the efficacy and safety of CTLA4-Ig in conditions such as psoriasis, graft versus host disease, lupus erythematosus, rheumatoid arthritis, and allergic conditions.

Main Methods:

  • CTLA4-Ig, an immunosuppressant immunoglobulin, is under development by Bristol-Myers Squibb.
  • A Phase II clinical trial has been initiated for psoriasis.
  • Collaborations are in place to explore indications including organ transplant rejection and autoimmune disorders.

Related Experiment Videos

Main Results:

  • The abstract does not contain specific results from clinical trials.
  • Development is ongoing across a range of inflammatory and autoimmune conditions.

Conclusions:

  • CTLA4-Ig shows promise as a treatment for a spectrum of immunological and autoimmune diseases.
  • Further clinical investigation, including Phase II trials for psoriasis, is underway to establish its therapeutic value.